Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Drops By 6.2%

Humacyte, Inc. (NASDAQ:HUMA) was the recipient of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 24,040,000 shares, a decrease of 6.2% from the January 15th total of 25,640,000 shares. Currently, 23.0% of the shares of the company are short sold. Based on an average daily trading volume, of 4,330,000 shares, the days-to-cover ratio is presently 5.6 days.

Institutional Investors Weigh In On Humacyte

A number of institutional investors have recently bought and sold shares of the business. Endowment Wealth Management Inc. increased its stake in Humacyte by 3.6% in the 4th quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock worth $526,000 after buying an additional 3,590 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Humacyte by 18.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock valued at $138,000 after purchasing an additional 4,327 shares in the last quarter. Beacon Pointe Advisors LLC grew its position in shares of Humacyte by 33.3% during the fourth quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock valued at $101,000 after purchasing an additional 5,000 shares in the last quarter. Rhumbline Advisers grew its position in shares of Humacyte by 4.6% during the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock valued at $578,000 after purchasing an additional 5,005 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in shares of Humacyte by 25.3% during the fourth quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock valued at $132,000 after purchasing an additional 5,293 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Stock Performance

Shares of Humacyte stock opened at $3.75 on Wednesday. Humacyte has a one year low of $2.81 and a one year high of $9.97. The stock’s fifty day moving average is $4.46 and its 200 day moving average is $5.20. The stock has a market cap of $471.98 million, a P/E ratio of -2.80 and a beta of 1.30.

Wall Street Analyst Weigh In

HUMA has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. Benchmark increased their price target on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Tuesday, January 21st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Humacyte currently has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.